tranexamic acid has been researched along with Angiohemophilia in 42 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Excerpt | Relevance | Reference |
---|---|---|
"These interim data suggest that recombinant VWF is not superior to tranexamic acid in reducing heavy menstrual bleeding in patients with mild or moderate von Willebrand disease." | 9.69 | Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial. ( Althouse, AD; Angelini, D; Bellissimo, D; Feldman, R; Humphreys, G; Hwang, N; Ivanco, D; Koerbel, G; Kraut, E; Kulkarni, R; Lasky, J; Leavitt, AD; Machin, N; Malec, L; Merricks, EP; Meyer, M; Nance, D; Nichols, TC; Philipp, C; Pruthi, R; Ragni, MV; Rothenberger, SD; Seaman, C; Sidonio, R; Smith, KJ; Vehec, D; Wheeler, AP; Xavier, F, 2023) |
"Tranexamic acid reduces blood loss in patients with bleeding diatheses and is used in a number of gynaecologic and non-gynaecologic conditions CASE: We discuss the case of a 27-year-old woman with type 1 von Willebrand disease, who presented with a two-year history of severe mittelschmerz secondary to recurrent hemorrhagic cysts." | 7.96 | Use of Tranexamic Acid for the Treatment of Mittelschmerz in a Patient with Type 1 von Willebrand Disease and Recurrent Hemorrhagic Cysts. ( Balayla, J; Gil, Y; Lasry, A, 2020) |
"To study the prophylactic effects of tranexamic acid (TXA) for reduction of bleeding episodes in patients with VWD and GT in non-invasive conditions." | 7.83 | Efficacy of tranexamic acid for the prevention of bleeding in patients with von Willebrand disease and Glanzmann thrombasthenia: a controlled, before and after trial. ( Bagheri, B; Eghbali, A; Melikof, L; Taherahmadi, H, 2016) |
"Four cases of menorrhagia in von Willebrand disease were successfully treated with tranexamic acid given in a single daily dose of 4 g for the first 3-5 days of the menstrual cycle." | 7.70 | Menorrhagia in von Willebrand disease successfully treated with single daily dose tranexamic acid. ( Hull, DR; Mayne, EE; Ong, YL, 1998) |
"These interim data suggest that recombinant VWF is not superior to tranexamic acid in reducing heavy menstrual bleeding in patients with mild or moderate von Willebrand disease." | 5.69 | Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial. ( Althouse, AD; Angelini, D; Bellissimo, D; Feldman, R; Humphreys, G; Hwang, N; Ivanco, D; Koerbel, G; Kraut, E; Kulkarni, R; Lasky, J; Leavitt, AD; Machin, N; Malec, L; Merricks, EP; Meyer, M; Nance, D; Nichols, TC; Philipp, C; Pruthi, R; Ragni, MV; Rothenberger, SD; Seaman, C; Sidonio, R; Smith, KJ; Vehec, D; Wheeler, AP; Xavier, F, 2023) |
" Prophylaxis (Desmopressin, clotting factor concentrates or tranexamic acid) to prevent bleeding was described in 100% (30/30) of EA procedures and in 4% (24/661) of hysterectomies." | 5.41 | Prophylactic and therapeutic strategies for intraoperative bleeding in women with von Willebrand disease and heavy menstrual bleeding: A systematic review. ( Bongers, MY; Eising, HP; Leemans, JC; Punt, MC, 2023) |
" Common dosage of tranexamic acid of 1 gram daily in 4 divided doses on days 1-5 of their menstrual cycles did not correct their menorrhagia." | 5.31 | High dose of tranexamic acid for treatment of severe menorrhagia in patients with von Willebrand disease. ( Mohri, H, 2002) |
" The highest-quality evidence is for the use of tranexamic acid in postpartum hemorrhage, which has been shown to decrease bleeding-related mortality in women without bleeding disorders." | 4.98 | Inherited Bleeding Disorders in the Obstetric Patient. ( Bannow, BS; Konkle, BA, 2018) |
"8%) had menorrhagia, for which combined oral contraceptives, tranexamic acid and desmopressin were the most common first-line therapies for menorrhagia, whereas VWF was third-line therapy reported in 13 women (1." | 4.93 | Von Willebrand factor for menorrhagia: a survey and literature review. ( Brambilla, DJ; James, AH; Kessler, CM; Konkle, BA; Kouides, PA; Machin, N; Malec, LM; Neff, AT; Philipp, CS; Ragni, MV, 2016) |
"Tranexamic acid reduces blood loss in patients with bleeding diatheses and is used in a number of gynaecologic and non-gynaecologic conditions CASE: We discuss the case of a 27-year-old woman with type 1 von Willebrand disease, who presented with a two-year history of severe mittelschmerz secondary to recurrent hemorrhagic cysts." | 3.96 | Use of Tranexamic Acid for the Treatment of Mittelschmerz in a Patient with Type 1 von Willebrand Disease and Recurrent Hemorrhagic Cysts. ( Balayla, J; Gil, Y; Lasry, A, 2020) |
"To study the prophylactic effects of tranexamic acid (TXA) for reduction of bleeding episodes in patients with VWD and GT in non-invasive conditions." | 3.83 | Efficacy of tranexamic acid for the prevention of bleeding in patients with von Willebrand disease and Glanzmann thrombasthenia: a controlled, before and after trial. ( Bagheri, B; Eghbali, A; Melikof, L; Taherahmadi, H, 2016) |
"Four cases of menorrhagia in von Willebrand disease were successfully treated with tranexamic acid given in a single daily dose of 4 g for the first 3-5 days of the menstrual cycle." | 3.70 | Menorrhagia in von Willebrand disease successfully treated with single daily dose tranexamic acid. ( Hull, DR; Mayne, EE; Ong, YL, 1998) |
"The most common form of BDs is von Willebrand Disease, reflecting 13% of adolescents with AUB." | 2.58 | Abnormal Uterine Bleeding including coagulopathies and other menstrual disorders. ( Deligeoroglou, E; Karountzos, V, 2018) |
"In vWD, the treatment of menorrhagia is usually medical, but there is lack of prospective data on the efficacy of commonly used medical therapies in these women." | 2.43 | Women and von Willebrand disease: controversies in diagnosis and management. ( Chi, C; Kadir, RA, 2006) |
"Tranexamic acid was usually added for mucosal surgery." | 2.41 | Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease. ( Griffioen, A; Harrington, C; Lee, CA; Nitu-Whalley, IC, 2001) |
"Peri-procedural management of von Willebrand disease (VWD) utilizes von Willebrand factor (VWF) concentrates or desmopressin (DDAVP) to increase VWF levels." | 1.91 | Desmopressin (DDAVP) use in patients with von Willebrand disease: A single-centre retrospective review of test response and clinical outcomes. ( Chandrakumaran, P; Hews-Girard, J; Poon, MC, 2023) |
"Our review of the literature and the results of the survey showed considerable heterogeneity in treatment regimens, and a lack of consistency in reporting of the variables that determine factor concentrate dosing and monitoring." | 1.43 | Practical aspects of factor concentrate use in patients with von Willebrand disease undergoing invasive procedures: a European survey. ( Altisent, C; Dolan, G; Katsarou, O; López Fernández, MF; Windyga, J; Zülfikar, B, 2016) |
"We have analyzed the databases for von Willebrand disease (VWD) from the hemophilia center for adult patients with bleeding disorders in South Australia." | 1.37 | Diagnosis and management of adult patients with von Willebrand disease in South Australia. ( Duncan, EM; Lloyd, JV; Mangos, HM; McRae, SJ; Rodgers, SE, 2011) |
"Hemophilia A and B and von Willebrand disease (VWD) belong to the most frequent congenital coagulation disorders and are a significant problem in patients who require periodontal therapy or tooth extraction." | 1.36 | Comprehensive treatment of periodontitis in patients with von Willebrand disease. ( Alesci, S; Eickholz, P; Miesbach, W; Nickles, K; Wohlfeil, M, 2010) |
" Common dosage of tranexamic acid of 1 gram daily in 4 divided doses on days 1-5 of their menstrual cycles did not correct their menorrhagia." | 1.31 | High dose of tranexamic acid for treatment of severe menorrhagia in patients with von Willebrand disease. ( Mohri, H, 2002) |
"A 42-year-old female with von Willebrand's disease was managed with desmopressin and tranexamic acid to aid haemostasis following a vaginal hysterectomy." | 1.31 | Severe hyponatraemia secondary to desmopressin therapy in von Willebrand's disease. ( Bertholini, DM; Butler, CS, 2000) |
"A patient with von Willebrand's disease had recurrent gastrointestinal bleeding from angiodysplasia, with inadequate response to von Willebrand factor substitution, medical and endoscopic treatment, and resection of affected bowel." | 1.31 | Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand's disease, controlled with recombinant factor VIIa. ( Meijer, K; Peters, FT; van der Meer, J, 2001) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (7.14) | 18.7374 |
1990's | 6 (14.29) | 18.2507 |
2000's | 11 (26.19) | 29.6817 |
2010's | 16 (38.10) | 24.3611 |
2020's | 6 (14.29) | 2.80 |
Authors | Studies |
---|---|
Brignardello-Petersen, R | 2 |
El Alayli, A | 2 |
Husainat, N | 2 |
Kalot, M | 1 |
Shahid, S | 2 |
Aljabirii, Y | 2 |
Britt, A | 2 |
Alturkmani, H | 2 |
El-Khechen, H | 2 |
Motaghi, S | 2 |
Roller, J | 2 |
Dimassi, A | 1 |
Abughanimeh, O | 1 |
Madoukh, B | 1 |
Arapshian, A | 1 |
Grow, JM | 1 |
Kouides, P | 3 |
Laffan, M | 1 |
Leebeek, FWG | 1 |
O'Brien, SH | 1 |
Tosetto, A | 2 |
James, PD | 2 |
Connell, NT | 2 |
Flood, V | 1 |
Mustafa, RA | 2 |
Kalot, MA | 1 |
Abdul-Kadir, R | 1 |
Couper, S | 1 |
Lavin, M | 3 |
Ozelo, MC | 1 |
Weyand, A | 1 |
Flood, VH | 1 |
Chandrakumaran, P | 1 |
Hews-Girard, J | 1 |
Poon, MC | 1 |
Ragni, MV | 2 |
Rothenberger, SD | 1 |
Feldman, R | 1 |
Nance, D | 1 |
Leavitt, AD | 1 |
Malec, L | 1 |
Kulkarni, R | 1 |
Sidonio, R | 1 |
Kraut, E | 1 |
Lasky, J | 1 |
Pruthi, R | 1 |
Angelini, D | 1 |
Philipp, C | 1 |
Hwang, N | 1 |
Wheeler, AP | 1 |
Seaman, C | 1 |
Machin, N | 2 |
Xavier, F | 1 |
Meyer, M | 1 |
Bellissimo, D | 1 |
Humphreys, G | 1 |
Smith, KJ | 1 |
Merricks, EP | 1 |
Nichols, TC | 1 |
Ivanco, D | 1 |
Vehec, D | 1 |
Koerbel, G | 1 |
Althouse, AD | 1 |
Eising, HP | 1 |
Punt, MC | 1 |
Leemans, JC | 1 |
Bongers, MY | 1 |
Lasry, A | 1 |
Gil, Y | 1 |
Balayla, J | 1 |
Scott, M | 1 |
Hay, CRM | 1 |
Elkhalifa, S | 1 |
Tower, C | 1 |
Cocker, M | 1 |
Thachil, J | 1 |
Deligeoroglou, E | 1 |
Karountzos, V | 1 |
Lewandowski, B | 1 |
Wojnar, J | 1 |
Brodowski, R | 1 |
Mucha, M | 1 |
Czenczek-Lewandowska, E | 1 |
Brzęcka, D | 1 |
Bannow, BS | 1 |
Konkle, BA | 2 |
Tiede, A | 2 |
van Galen, KP | 1 |
Engelen, ET | 1 |
Mauser-Bunschoten, EP | 1 |
van Es, RJ | 1 |
Schutgens, RE | 1 |
Malec, LM | 1 |
James, AH | 1 |
Kessler, CM | 1 |
Kouides, PA | 1 |
Neff, AT | 1 |
Philipp, CS | 1 |
Brambilla, DJ | 1 |
Appelmann, I | 1 |
Kreher, S | 1 |
Parmentier, S | 1 |
Wolf, HH | 1 |
Bisping, G | 1 |
Kirschner, M | 1 |
Bergmann, F | 1 |
Schilling, K | 1 |
Brümmendorf, TH | 1 |
Petrides, PE | 1 |
Matzdorff, A | 1 |
Griesshammer, M | 1 |
Riess, H | 1 |
Koschmieder, S | 1 |
Windyga, J | 1 |
Dolan, G | 1 |
Altisent, C | 1 |
Katsarou, O | 1 |
López Fernández, MF | 1 |
Zülfikar, B | 1 |
Eghbali, A | 1 |
Melikof, L | 1 |
Taherahmadi, H | 1 |
Bagheri, B | 1 |
Sánchez-Luceros, A | 1 |
Woods, AI | 1 |
Bermejo, E | 1 |
Shukla, S | 1 |
Acharya, S | 1 |
Rydz, N | 1 |
Othman, M | 1 |
O'Donnell, JS | 1 |
Nickles, K | 1 |
Wohlfeil, M | 1 |
Alesci, S | 1 |
Miesbach, W | 1 |
Eickholz, P | 1 |
Mikhail, S | 1 |
Rodgers, SE | 1 |
Lloyd, JV | 1 |
Mangos, HM | 1 |
Duncan, EM | 1 |
McRae, SJ | 1 |
Nair, SC | 1 |
Viswabandya, A | 1 |
Srivastava, A | 2 |
Jiménez-Yuste, V | 1 |
Prim, MP | 1 |
De Diego, JI | 1 |
Villar, A | 1 |
Quintana, M | 1 |
Rabanal, I | 1 |
Sastre, N | 1 |
Hernández-Navarro, F | 1 |
Mohri, H | 1 |
Mannucci, PM | 2 |
Morimoto, Y | 1 |
Yoshioka, A | 1 |
Sugimoto, M | 1 |
Imai, Y | 1 |
Kirita, T | 1 |
Kadir, RA | 1 |
Chi, C | 1 |
Castaman, G | 1 |
Rodeghiero, F | 1 |
Cappelletti, A | 1 |
Baudo, F | 1 |
Eikenboom, JC | 2 |
Federici, AB | 2 |
Lethagen, S | 1 |
Linari, S | 1 |
Lusher, J | 1 |
Nishino, M | 1 |
Petrini, P | 1 |
Ungerstedt, JS | 1 |
Jackson, N | 1 |
Hashim, ZA | 1 |
Zainal, NA | 1 |
Jamaluddin, N | 1 |
Prinsley, P | 1 |
Wood, M | 1 |
Lee, CA | 2 |
Ong, YL | 1 |
Hull, DR | 1 |
Mayne, EE | 1 |
Onundarson, PT | 1 |
Baerlocher, GM | 1 |
Leoncini-Franscini, L | 1 |
Wuillemin, WA | 1 |
Furlan, M | 1 |
Sacco, R | 1 |
Stabile, F | 1 |
Carpenedo, M | 1 |
Zingaro, E | 1 |
Bertholini, DM | 1 |
Butler, CS | 1 |
Nitu-Whalley, IC | 1 |
Griffioen, A | 1 |
Harrington, C | 1 |
Stubbs, M | 1 |
Lloyd, J | 1 |
Meijer, K | 1 |
Peters, FT | 1 |
van der Meer, J | 1 |
Nilsson, IM | 1 |
Mikaelsson, M | 1 |
Vilhardt, H | 1 |
Walter, H | 1 |
van der Meer, FJ | 1 |
Briët, E | 1 |
Pignanelli, M | 1 |
Rota, L | 1 |
Pignanelli, C | 1 |
Vinckier, F | 1 |
Vermylen, J | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Prospective, Randomized, Crossover Trial Comparing Recombinant Von Willebrand Factor (rVWF) vs. Tranexamic Acid (TA) to Minimize Menorrhagia in Women With Von Willebrand Disease: The VWD Minimize Study[NCT02606045] | Phase 3 | 60 participants (Anticipated) | Interventional | 2019-02-07 | Active, not recruiting | ||
National Study of Moderate and Severe Von Willebrand Disease in the Netherlands[NCT00510042] | 1,100 participants (Anticipated) | Observational | 2007-07-31 | Completed | |||
Type 3 Von Willebrand International Registries Inhibitor Prospective Study[NCT02460458] | 265 participants (Actual) | Observational | 2012-11-05 | Active, not recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Measurement of Factor VIII (FVIII) Amidolytic Activity (FVIII:Am) in the blood through chromogenic test. Only patients with FVIII:Am less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
Intervention | IU/dL (Mean) |
---|---|
Type 3 Von Willebrand's Disease (VWD3) | 1.63 |
Measurement of the amount of Factor VIII (FVIII) protein in the blood through FVIII:Ag test. Only patients with FVIII:Ag less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
Intervention | IU/dL (Mean) |
---|---|
Type 3 Von Willebrand's Disease (VWD3) | 3.64 |
Measurement of the Factor VIII (FVIII) Procoagulant Activity (FVIII:C) in the blood through one-stage clotting test. Only patients with FVIII:C less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
Intervention | IU/dL (Mean) |
---|---|
Type 3 Von Willebrand's Disease (VWD3) | 2.43 |
Measurement of Von Willebrand Factor (VWF) Propeptide levels in the blood through VWF Propeptide test. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
Intervention | IU/dL (Mean) |
---|---|
Type 3 Von Willebrand's Disease (VWD3) | 7.3 |
Measurement of the amount of Von Willebrand Factor (VWF) protein in the blood through Von Willebrand Factor Antigen (VWF:Ag) test. Only patients with VWF:Ag less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
Intervention | IU/dL (Mean) |
---|---|
Type 3 Von Willebrand's Disease (VWD3) | 1.29 |
"Number of patients for who the following tests have been performed:~Hemoglobin (mmol/L), Hemagglutination Titer (HT) (%), Mean Corpuscular Volume (MVC) (fl), Leucocytes (E9/L), Neutrophils (%), Basophils (%), Eosinophils (%), Lymphocytes (%), Platelet Count (E9/L), Mean Platelet Volume (MPV) (fl), Prothrombin Time (sec), Partial Thromboplastin Time (PTT) (sec), Partial Thromboplastin Time Mix 50:50 (PTT mix 50:50) (sec), Ferritin (ug/l), Bleeding Time (min:sec), Closure Time (sec), Collagen/ADP (sec), Collagen/Epinephrine (sec); Factor VIII Procoagulant Activity (FVIII:C) (IU/mL), Von Willebrand Factor Ristocetin Cofactor (VWF:RCo) (IU/mL), Won Willebrand Factor Antigen (VWF:Ag) (IU/mL)." (NCT02460458)
Timeframe: 24 months (retrospective phase)
Intervention | Participants (Count of Participants) |
---|---|
Type 3 Von Willebrand's Disease (VWD3) | 265 |
Evaluation of the titre of Anti-Von Willebrand Factor (anti-VWF) Antibodies through Bethesda Test. (NCT02460458)
Timeframe: 24 months (retrospective phase)
Intervention | Participants (Count of Participants) |
---|---|
Type 3 Von Willebrand's Disease (VWD3) | 4 |
Record of any allergic and anaphylactic reactions occurred in the past due to the use of any Von Willebrand Factor (VWF) concentrate and the date of onset. (NCT02460458)
Timeframe: 24 months (retrospective phase)
Intervention | Participants (Count of Participants) |
---|---|
Type 3 Von Willebrand's Disease (VWD3) | 41 |
Record of any product used during the retrospective phase (collected type of blood products/Von Willebrand Factor (VWF) concentrate, year of first exposure, units used). (NCT02460458)
Timeframe: 24 months (retrospective phase)
Intervention | Participants (Count of Participants) | |||
---|---|---|---|---|
Packed red cells | Cryoprecipitates | Fresh frozen plasma | Platelet concentrates | |
Type 3 Von Willebrand's Disease (VWD3) | 24 | 123 | 10 | 1 |
12 reviews available for tranexamic acid and Angiohemophilia
Article | Year |
---|---|
Surgical management of patients with von Willebrand disease: summary of 2 systematic reviews of the literature.
Topics: Factor VIII; Hemostasis; Humans; Tranexamic Acid; von Willebrand Diseases; von Willebrand Factor | 2022 |
Prophylactic and therapeutic strategies for intraoperative bleeding in women with von Willebrand disease and heavy menstrual bleeding: A systematic review.
Topics: Female; Hemorrhage; Humans; Menorrhagia; Prospective Studies; Tranexamic Acid; von Willebrand Diseas | 2023 |
Abnormal Uterine Bleeding including coagulopathies and other menstrual disorders.
Topics: Adolescent; Antifibrinolytic Agents; Contraceptives, Oral, Combined; Female; Humans; Menorrhagia; Me | 2018 |
Inherited Bleeding Disorders in the Obstetric Patient.
Topics: Blood Coagulation; Deamino Arginine Vasopressin; Female; Fibrinolytic Agents; Hematology; Hemophilia | 2018 |
Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Factor IX; Factor VIII; Hemophilia | 2015 |
Von Willebrand factor for menorrhagia: a survey and literature review.
Topics: Antifibrinolytic Agents; Contraceptives, Oral; Databases, Factual; Deamino Arginine Vasopressin; Fem | 2016 |
Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis
Topics: Anticoagulants; Antineoplastic Agents; Blood Coagulation Factors; Blood Loss, Surgical; Blood Transf | 2016 |
New treatment approaches to von Willebrand disease.
Topics: Deamino Arginine Vasopressin; Hemorrhage; Humans; Tranexamic Acid; von Willebrand Diseases; von Will | 2016 |
Diagnosis and management of von Willebrand disease: a developing country perspective.
Topics: Clinical Laboratory Techniques; Coagulants; Deamino Arginine Vasopressin; Developing Countries; Fact | 2011 |
Treatment of von Willebrand's Disease.
Topics: Aminocaproates; Blood Component Transfusion; Deamino Arginine Vasopressin; Factor VIII; Female; Hemo | 2004 |
Treatment of von Willebrand's Disease.
Topics: Aminocaproates; Blood Component Transfusion; Deamino Arginine Vasopressin; Factor VIII; Female; Hemo | 2004 |
Treatment of von Willebrand's Disease.
Topics: Aminocaproates; Blood Component Transfusion; Deamino Arginine Vasopressin; Factor VIII; Female; Hemo | 2004 |
Treatment of von Willebrand's Disease.
Topics: Aminocaproates; Blood Component Transfusion; Deamino Arginine Vasopressin; Factor VIII; Female; Hemo | 2004 |
Women and von Willebrand disease: controversies in diagnosis and management.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Contraceptives, Oral, Synthetic; Deamino Arginine Vasopr | 2006 |
Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease.
Topics: Anesthesia, Obstetrical; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Deamino Ar | 2001 |
2 trials available for tranexamic acid and Angiohemophilia
Article | Year |
---|---|
Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial.
Topics: Adolescent; Adult; Cross-Over Studies; Female; Hemorrhage; Humans; Menorrhagia; Middle Aged; Tranexa | 2023 |
Optimising local therapy during oral surgery in patients with von Willebrand disease: effective results from a retrospective analysis of 63 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Deamino Arginine Vasopressin; D | 2000 |
28 other studies available for tranexamic acid and Angiohemophilia
Article | Year |
---|---|
Gynecologic and obstetric management of women with von Willebrand disease: summary of 3 systematic reviews of the literature.
Topics: Female; Humans; Menorrhagia; Postpartum Hemorrhage; Pregnancy; Systematic Reviews as Topic; Tranexam | 2022 |
Desmopressin (DDAVP) use in patients with von Willebrand disease: A single-centre retrospective review of test response and clinical outcomes.
Topics: Adolescent; Adult; Deamino Arginine Vasopressin; Factor VIII; Hemorrhage; Humans; Retrospective Stud | 2023 |
Use of Tranexamic Acid for the Treatment of Mittelschmerz in a Patient with Type 1 von Willebrand Disease and Recurrent Hemorrhagic Cysts.
Topics: Adult; Cysts; Female; Hemorrhage; Humans; Ovulation; Pain; Pelvic Pain; Tranexamic Acid; Treatment O | 2020 |
Management of pregnancy in type 3 von Willebrand disease with alloantibodies.
Topics: Adult; Disease Management; Factor VIIa; Female; Humans; Isoantibodies; Platelet Transfusion; Pregnan | 2018 |
Dental extractions in patients with mild hemophilia A and hemophilia B and von Willebrand disease without clotting factor supplementation.
Topics: Adult; Antifibrinolytic Agents; Blood Coagulation Disorders, Inherited; Dental Caries; Female; Hemop | 2018 |
Diagnosis and treatment of acquired von Willebrand syndrome.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Child; Child, Preschool; Deamino Arginine V | 2012 |
Practical aspects of factor concentrate use in patients with von Willebrand disease undergoing invasive procedures: a European survey.
Topics: Antifibrinolytic Agents; Clinical Trials as Topic; Coagulants; Databases, Factual; Dose-Response Rel | 2016 |
Efficacy of tranexamic acid for the prevention of bleeding in patients with von Willebrand disease and Glanzmann thrombasthenia: a controlled, before and after trial.
Topics: Antifibrinolytic Agents; Child, Preschool; Controlled Before-After Studies; Double-Blind Method; Fem | 2016 |
PT-VWD posing diagnostic and therapeutic challenges - small case series.
Topics: Adolescent; Child, Preschool; Deamino Arginine Vasopressin; Drug Therapy, Combination; Factor VIIa; | 2017 |
Comprehensive treatment of periodontitis in patients with von Willebrand disease.
Topics: Adult; Aggregatibacter actinomycetemcomitans; Aggressive Periodontitis; Anti-Bacterial Agents; Chron | 2010 |
von Willebrand disease in the pediatric and adolescent population.
Topics: Adolescent; Aminocaproic Acid; Antifibrinolytic Agents; Child; Contusions; Deamino Arginine Vasopres | 2010 |
Diagnosis and management of adult patients with von Willebrand disease in South Australia.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Databases, Factual; Deamino Arginine Vasopr | 2011 |
Otolaryngologic surgery in children with von Willebrand disease.
Topics: Adenoidectomy; Adolescent; Antifibrinolytic Agents; Child; Child, Preschool; Deamino Arginine Vasopr | 2002 |
High dose of tranexamic acid for treatment of severe menorrhagia in patients with von Willebrand disease.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; | 2002 |
Haemostatic management of intraoral bleeding in patients with von Willebrand disease.
Topics: Adolescent; Adult; Child; Deamino Arginine Vasopressin; Dental Care for Chronically Ill; Factor VIII | 2005 |
Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study.
Topics: Adolescent; Adult; Aged; Case-Control Studies; Child; Child, Preschool; Deamino Arginine Vasopressin | 2006 |
Puerperal acquired factor VIII inhibitor causing a von Willebrand-like syndrome in a patient with anti-DNA antibodies.
Topics: Adult; Antibodies, Antinuclear; Factor VIII; Female; Gingival Hemorrhage; Humans; Lupus Erythematosu | 1995 |
Adenotonsillectomy in patients with inherited bleeding disorders.
Topics: Adenoidectomy; Blood Coagulation Disorders; Child; Child, Preschool; Deamino Arginine Vasopressin; F | 1993 |
Menorrhagia in von Willebrand disease successfully treated with single daily dose tranexamic acid.
Topics: Administration, Oral; Adolescent; Adult; Antifibrinolytic Agents; Drug Administration Schedule; Fema | 1998 |
Treatment of menorrhagia in von Willebrand's disease.
Topics: Adult; Antifibrinolytic Agents; Female; Humans; Menorrhagia; Tranexamic Acid; von Willebrand Disease | 1999 |
[Patient with recurrent gastrointestinal hemorrhage in acquired von Willebrand disease].
Topics: Autoantibodies; Female; Gastrointestinal Hemorrhage; Humans; Middle Aged; Recurrence; Tranexamic Aci | 1999 |
Severe hyponatraemia secondary to desmopressin therapy in von Willebrand's disease.
Topics: Acute Disease; Adult; Deamino Arginine Vasopressin; Female; Hemostatics; Humans; Hyponatremia; Hyste | 2000 |
A protocol for the dental management of von Willebrand's disease, haemophilia A and haemophilia B.
Topics: Adolescent; Adult; Aged; Antifibrinolytic Agents; Clinical Protocols; Deamino Arginine Vasopressin; | 2001 |
Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand's disease, controlled with recombinant factor VIIa.
Topics: Angiodysplasia; Blood Transfusion; Combined Modality Therapy; Deamino Arginine Vasopressin; Estrogen | 2001 |
DDAVP factor VIII concentrate and its properties in vivo and in vitro.
Topics: Adolescent; Aged; Arginine Vasopressin; Blood Coagulation; Blood Donors; Child; Deamino Arginine Vas | 1979 |
Acquired von Willebrand's disease due to excessive fibrinolysis.
Topics: Blood Coagulation Disorders; Fibrinolysis; Hemorrhagic Disorders; Humans; Male; Middle Aged; Tranexa | 1992 |
[Extractions in hemophilic patients. Control of hemostasis with DDAVP].
Topics: Adolescent; Adult; Child; Deamino Arginine Vasopressin; Dental Care for Disabled; Hemophilia A; Hemo | 1988 |
Dental extractions in hemophilia: reflections on 10 years' experience.
Topics: Aminocaproic Acid; Bandages; Cellulose, Oxidized; Dental Care for Disabled; Factor IX; Factor VIII; | 1985 |